RXi Pharmaceuticals announces positive results from phase 2 trial with Samcyprone™
RXi Pharma announced positive results with its lead clinical compound RXI-109 in a Phase 2 clinical trial. RXI-109-1402 is an open-label, multi-center, prospective, within-subject controlled study evaluating effectiveness and safety of RXI-109 on the outcome of scar revision surgery. May 18, 2018